Stryker Q4 organic sales up 11.4%; FY23 revenue $20.5B; guides FY24 adj EPS $11.70-$12.00

STRYKER CORP

2023-FY EPS reported $8.25 revenue$20,498,000,000

Q4 organic net sales growth 11.4% to $5.8B; full year organic growth 11.5% to $20.5B.
Q4 adjusted EPS $3.46 (+15.3% YoY); full year adjusted EPS $10.60 (+13.5%).
Adjusted operating margin expanded 60 bps in Q4 to 27.2%; full year 24.2% (+40 bps).
MedSurg & Neuro organic sales up 11.8% in Q4 and full year; Ortho & Spine up 10.7% Q4, 11.1% FY.
FY2024 outlook: organic sales growth 7.5%-9.0%; adjusted EPS $11.70-$12.00.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

STRYKER CORP updated its the fourth quarter and full year of 2023 guidance (reaffirmed).

Period: the fourth quarter and full year of 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Stryker Corporation issued a press release on January 30, 2024 announcing its fourth quarter and full-year 2023 operating results and 2024 outlook.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

STRYKER CORP filing history →

Source: SEC EDGAR

accession 0000310764-24-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.